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Severe visual impairment, partial sight, or low vision (LV)—
call it what you like, the long-term reduction in visual func-
tion takes a large toll on the affected individuals, their fami-
lies, and society in general.
Lossof independence,unem-
ployment,depression,and in-
creased mortality and morbidity all contribute to a dimin-
ishedqualityof life that characterizesLV.The total annual cost
of low vision in the United States is estimated to be $5.5 bil-
lion plus an additional $10 billion due to lost quality-adjusted
life years.1
Low-visionrehabilitation (LVR)hasbeenavailable, albeit at
acosttothepatient,sincethelatterhalfofthe20thcenturywhen
the sight-savingphilosophy thatwaspervasive at the timewas
pushed aside in favor of sight-maximizing strategies. Yet with
morethan6decadesofexperiencewithLVR, there isstilldebate
whetherLVRiseffectiveand, if so,onhowitshouldbeprovided,
bywhom,and forwhom.There is a consensus that LVRshould
bemultidisciplinaryandthat it shouldbestartedearly,possibly
beforeastableendstageofvisual impairments.However,theevi-
dencesupportingtheconsensusopinionisscarce. In2012,asys-
tematic reviewof theeffectivenessofLVserviceprovision iden-
tifiedonly52relevantstudies,andofthese,only7metthehigher
standards of a randomized clinical trial.2
Fortunately, the emphasis on sound evidence has spread
to LV research. It is widely recognized that high-quality evi-
dence, including from randomized clinical trials, is needed if
weare to convincehealth care commissioners, insurancecom-
panies, andgovernmentofficials to support LVR.Wehavenew
instruments formeasuringdisability due toLV, and thesenew
instrumentsarebeingused toevaluate theeffectivenessofLVR
provided by the US Department of Veterans Affairs, which is
a pioneer in LV service provision in the United States.
Stelmack et al3 documented large improvements in pa-
tients’ visual ability in 4 domains: reading, visual informa-
tion processing, mobility, and visual motor skills following 4
to 6 weeks of inpatient LVR provided at residential blindness
rehabilitation centers. That study was followed by the Veter-
ansAffairs LowVision InterventionTrial (LOVIT)4 conducted
at 2 outpatient VA centers. LOVIT was a randomized clinical
trial with patients randomized to LVR or a waiting list for 4
months.Thepatients in the treatmentgroup received5weekly
2-hour sessions with the therapists plus 5 hours of home-
work perweek. The same instrumentswere used to assess vi-
sual ability and, although the effects were smaller than those
for the residential program, they were still judged to be clini-
cally meaningful and statistically significant. Outcome mea-
sures for LOVIT were based entirely on patient-reported out-
comes (questionnaires) and, given the lack ofmasking for the
treatmentgroup, the studywas subject toHawthorneeffects—
the tendency to show an improvement due to being the sub-
ject of attention in a study.
In this issue of JAMA Ophthalmology, Stelmack and
colleagues5 report on LOVIT II. This trial reduced the treat-
ment to 1 to 3 therapy sessions with approximately 10 home-
work assignments. The control group was provided with the
same LV aids as the treatment group but no additional LVR or
homework. The effect of the additional training diminishes
compared with the effect achieved with LOVIT but is still
deemed to be clinically meaningful and statistically signifi-
cant. Again, the interviewers weremasked but the therapists
and participants were not. Fortunately, the patient-reported
outcomeswere supplemented by ameasure of actual reading
performance (MNREADtest)6 and, although theeffect sizewas
smaller forMNREADthan for self-reportedvisual ability, there
was a clinically meaningful and statistically significant im-
provement in readingspeedandreadingacuity thatwasgreater
in the treatment group than in the control group.
Taken together, these 3 studies provide convincing evi-
dence that LVR can improve visual ability. Several important
questions remain:
1. Who benefits from LVR?Having been carried out in the VA
setting, more than 90% of the participants in the 3 studies
were white males, all with macular disease. Do the results
generalize towomen and to the nonwhite population or to
thosewithothereyeconditions? Inaddition,LOVIT II found
that LVR was effective only for patients with best-
corrected acuityworse than 20/63.When in the course of a
progressive eye disease should LVR be started?
2. What elements of LVRare critical for success?These 3 stud-
ies spanned the range fromamonth of inpatient treatment
to 1- to 3-hour therapy sessions provided in an outpatient
setting. Howmuch LVR is required? Is homework critical?
Might homework be sufficient?
3. Low-vision services in the VA system provide all pre-
scribed LVdevices to the veteran free of charge. Elsewhere
in theUnitedStates,most LV services charge thepatient for
thedevice, sometimesatahighly inflatedprice tohelpcover
the costs of providing the service. The VA services dis-
pensemore-expensiveLVaids, suchas telescopes andelec-
tronic devices, that are more likely to be beneficial with
training than simple hand and stand magnifiers.
4. What outcomes should be evaluated andhow?These stud-
ies focusedonself-reported readingability.Whyrelyonself-
report when we have several validated reading tests—
MNREAD, International Reading Speed Texts,7 and the
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Radner test,8 among others? One argument is that highly
standardized reading tests are not representative of actual
reading tasks. However, it has been shown that perfor-
mance on clinical reading tests is indicative of reading per-
formance at home,9 although there are significant discrep-
ancies between self-reported reading ability andmeasured
reading speed.
5. Is LVR cost-effective? How long do the effects last? LOVIT
II included a quality-of-life scale and a health utility mea-
sure, presumably to be used in a health economic evalua-
tion.However, neither of these tools showed any improve-
ment and received little further attention.
These questionsnotwithstanding, the LOVIT studies rep-
resent a major contribution to the evidence base for LVR.
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